Results 301 to 310 of about 55,676 (335)

Acute retinal necrosis during the systemic use of Janus kinase inhibitor. [PDF]

Int J Retina Vitreous
Watanabe D, Namba K, Hase K, Suzuki K, Ogino Y, Saito M, Iwata D, Mizuuchi K, Hiraoka M, Narita M, Kitaichi N, Kitaya N, Ishida S.   +12 more
europepmc   +1 more source

Expression of periostin and podoplanin in canine testicular tumours. [PDF]

BMC Vet Res
Ciaputa R, Janus-Ziółkowska I, Żebrowski K, Nowak M, Dzimira S, Piotrowska A, Ratajczak-Wielgomas K, Kandefer-Gola M, Grieco V.   +8 more
europepmc   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study.

JMIR Res Protoc
Mellenthin C, Schaller F, Vignot L, Peisl S, Vesce R, Esposito I, Gonelle-Gispert C, Schneider C, Adamina M, Bühler LH.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Janus-Kinase-Hemmer

Zeitschrift für Rheumatologie, 2012
Die Janus-Kinase-Inhibitoren stellen einen neuen therapeutischen Ansatz in der Behandlung der rheumatoiden Arthritis dar. In Phase-II- und -III-Studien zu Tofacitinib zeigte sich eine gute klinische Wirksamkeit mit einem ACR (American College of Rheumatology)-20-Ansprechen von > 50% sowohl fur die Mono- als auch die Kombinationstherapie mit Methotrexat.
E. Ostermeier, P. Roll, H.-P. Tony
openaire   +1 more source

Janus Kinase Mutations

Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire   +2 more sources

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources